X-Nico

2 unusual facts about Atypical hemolytic uremic syndrome


Atypical hemolytic uremic syndrome

Comorbidities in this study included malignant hypertension (30%), TMA with a history of transplant (23%), TMA associated with pregnancy (21%), glomerulopathy (17%), systemic disease such as SLE or PSS (6%), and malignancy (1%).

Before the introduction of eculizumab (INN and USAN, trade name Soliris), a monoclonal antibody that is a first-in-class terminal complement inhibitor, management options for patients with aHUS were extremely limited.



see also